Mathews, V <br/><br/>
Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.  [electronic resource] 

 -  Leukemia  May 2006 
 - 881-3 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Letter 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2404165  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Arsenic Trioxide<br/>Arsenicals--administration & dosage<br/>Chemical and Drug Induced Liver Injury--complications<br/>Cohort Studies<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Genetic Predisposition to Disease<br/>Humans<br/>Incidence<br/>Leukemia, Promyelocytic, Acute--diagnosis<br/>Liver--drug effects<br/>Liver Function Tests<br/>Male<br/>Methylenetetrahydrofolate Reductase (NADPH2)--genetics<br/>Oxides--administration & dosage<br/>Polymorphism, Genetic<br/>Remission Induction<br/>Risk Factors<br/>Survival Rate<br/>Treatment Outcome